Outsourcer Mitie warns on profits

Groups find home care budgets tighter than expected

Europe embraces biotech boom

Belgian diagnostics group Biocartis plans IPO

UnitedHealth: changing the channel

The drug supply chain is becoming even trickier

Healthcare sector leads feverish M&A activity

Sector racks up 70% increase in value of deals

UnitedHealth pays $13bn for drugs manager

Teva, Novartis and Horizon add to latest episode of consolidation

Co-pilot suffered suicidal tendencies

Lubitz had psychotherapy several years ago, say prosecutors

Medics welcome GSK meningitis B drug deal

UK will be first country with nationwide programme

City accused of failing life sciences

Sector too dependent on GSK and AstraZeneca, says top scientist

Brics banker goes to war on superbugs

Jim O’Neill is leading the drive to tackle drug-resistant superbugs

Andreas Lubitz

Fears raised over pilot test reliability

Potential weaknesses highlighted in airlines’ fitness checks

Insulin: moving the needle

One of the most lucrative pharma markets is about to change

Actavis rewrites ‘big pharma’ playbook

Big, lean dealmakers are reshaping the drugs industry — but are they running out of targets?

The last bell tolls for the lethal injection

Pharmaceutical companies have become reluctant to be associated with state-sanctioned killing

Drugs groups unite to mine genetic data

Pharmaceuticals groups form partnership to assist UK government’s 100,000 Genomes Project

Moulton-backed RedX Pharma to list on Aim

UK life science industry shows sign of life beyond southeast

Ranbaxy pledges to regain US trust

Sun Pharma wins go-ahead to complete takeover of troubled group

The value of a life is not about cost

Tenet/United Surgical: knife edge

No one wants to pay for long hospital stays

Pharmacyclics boss reaps $3.6bn from bid

AbbVie $21bn bid delivers almost $4bn to executives

Silicon Valley lands on big pharma’s turf

Tech industry’s turn to healthcare unsettles drugmakers


More FT Twitter accounts